The first known ChAdOx1 nCoV-19 vaccine-induced thrombotic thrombocytopenia in Australia

Jay Hocking, Sanjeev Daya Chunilal, Vivien Chen, Tim Brighton, James Nguyen, Joycelyn Tan, Stephen B N Ting and Huyen Tran
Med J Aust
Published online: 7 May 2021

This is a preprint version of an article submitted for publication in the Medical Journal of Australia. Changes may be made before final publication. Click here for the PDF version. Suggested citation: Hocking J, Chunilal SD, Chen V, Brighton T, Nguyen J, Tan J, Ting SBN, Tran H. The first known ChAdOx1 nCoV-19 vaccine-induced thrombotic thrombocytopenia in Australia. Med J Aust 2021; [Preprint, 7 May 2021].


In March 2021, Australia began the role out of the ChAdOx1 nCoV-19 vaccine to combat the COVID-19 pandemic. In Europe where more than 20 million doses of this vaccine had been administered by mid-March 2021, case reports of thrombosis at unusual sites associated with thrombocytopenia, occurring day 4 to 28 post vaccination with a mortality rate of up to 25%, at an estimated rate of 1:100,000 were being received (1).

In Australia, ChAdOx1 nCoV-19 vaccine was initially offered to highest-at-risk professions without age restriction. By the end of March 2021, approximately 350,000 first dose of ChAdOx1 nCoV-19 vaccine had been administered Australia wide. Here we report the first known Australasian case of ChAdOx1 nCoV-19 vaccine-induced thrombotic thrombocytopenia (VITT).

Case report

Clinical record

A 44-year-old male health care worker presented with fevers, fatigue, head “fogginess” with abdominal discomfort and increased bowel frequency eight days after receiving his first dose of the ChAdOx1 nCoV-19 vaccine. He was previously well with a past history of depression, and only taking escitalopram.. He had no prior thrombosis or exposure to heparin. The low platelet count, 70x109/L (RR, 150-400 x109/L) and markedly elevated D-dimer 114 mg/L (ULN, 0.5) with vague abdominal pains prompted a CT-venogram of the abdomen that demonstrated thrombosis with complete occlusion of the portal and splenic veins, and protrusion of a tongue of thrombus into the superior mesenteric vein (SMV) (Figure 1 - available in PDF). CT-venogram of the head did not show central venous sinus thrombosis.

The rest of the full blood count and the blood film showed no microangiopathic features. The prothrombin time, activated partial thromboplastin and fibrinogen levels, liver and renal function tests were all normal. Antiphospholipid antibodies were negative and heterozygous prothrombin G20210A mutation identified. Antibodies to the SARS-CoV-2 nucleocapsid protein and COVID-respiratory PCR were negative ruling out active COVID-19 infection as a potential thrombosis aetiology.

Antibodies to the heparin platelet factor 4 (PF4) complex in patient plasma was strongly positive (OD 1.94) by ELISA (Asserachrom™ HPIA IgG). Three functional assays, including serotonin release assay (SRA, Hidex 300 SL™), MEA (Roche diagnostics™) and flow cytometry (BD Fortessa, procoagulant assay) all detected heparin-independent platelet-factor 4 (PF4) antibody complexes that activated donor platelets (2).


Immediate anticoagulation was started with the anti-FXa agent, fondaparinux 10 mg (weight: 105kg) subcutaneously 24 hourly and intravenous Immunoglobulin (IVIG), 1 g/kg administered on days two and three, and repeated days seven and eight post admission. Despite achieving an anti-FXa fondaparinux level 6 hours post dose of 0.94U/mL (target range 0.50 – 1.20), the platelets remained between  6-20 x 109/L for the initial six days. The patient subsequently developed an acute abdomen clinically and a repeat CT scan showed extension and occlusive thrombus into the SMV with venous outlet obstruction and bowel ischaemic features. He underwent an immediate laparotomy with resection of 1.8 m of ischaemic bowel. Contemporaneously, given clot extension had occurred on fondaparinux, anticoagulation was changed to  thrombin inhibitor, bivalirudin where its short half-life (25 minutes) allowed for titratable perioperative anticoagulation and an intravenous pulse of methylprednisolone 1g administered to augment PF4 antibody immunosuppression.

The patient returned to theatre 48h later  where further compromised bowel was resected. Methylprednisolone 1g daily was reinstituted for four days with a  an immediate platelet peak s  to 385 x109/L at completion of this four-day pulse. To date he is recovering well without further complications. He has transitioned to warfarin to be continued and monitored   in haematology outpatients.  Figure 2 (available in PDF) summarises the time course of treatment and response.


This is the first reported case of thrombosis at an unusual site with thrombocytopenia following ChAdOx1 nCoV-19 vaccination in Australia. The temporal association, the detection of anti-PF4 antibodies with platelet activation in absence of heparin which is neutralised at high-dose heparin is consistent with the most recent reports (3). This entity, currently labelled as VITT has pathologic similarity to autoimmune Heparin induced Thrombocytopenia (HIT) –but without prior heparin exposure. More evidence is needed to demonstrate if the serum of VITT patients, contain antibodies that can bind to PF4 independent of heparin, following vaccination against COVID-19. Further, the mechanism responsible for profound platelet activation following ChAdOx1 nCoV-19 vaccination as evidenced  by ELISA high optical densities remains to be established (3). To the best of our current knowledge, there are no reported VITT cases with m-RNA COVID-19 vaccines.

It is doctrine in the management of HIT that in addition to immediate cessation of all heparins, a non-heparin anticoagulant is commenced to prevent (further) thrombosis Given the pathogenic similarities of VITT cases to HIT, we initially used fondaparinux as our patient at presentation was clinically stable with normal renal function. It is unclear if the clinical deterioration in our patient despite achieving favourable therapeutic fondaparinux drug level was resultant of anti-Xa drug(s) non-efficacy and/or because of the severity of venous outflow obstruction with compromised ischaemic small bowel. In principle, the surgical removal of any ischaemic tissue would be associated with clinical improvement.

The benefit of IVIG remains debatable but in vitro spiking experiments and observation of platelet increment after its administration suggests that there may be a role (3, 4). It is possible that IVIG displaces the binding of anti-PF4 antibody complex to FcgammaRIIA receptors on platelets (5). In our case, it is difficult to ascribe a specific clinical and platelet recovery to IVIG solely given the simultaneous timing of surgical removal of ischaemic intestine, the commencement of alternate anticoagulation with bivalirudin and pulsed high dose steroids. It is noted that pulsed methylprednisolone was prescribed in the majority of recently reported cases (3).

 In line with evolving guidance documents, clinicians assessing patients who present with organ-specific thrombotic symptoms, 4 to 28 days following ChAdOx1 nCoV-19 vaccination should look for any combination of thrombocytopenia and elevated D-dimer, and/or low fibrinogen with a low threshold for requesting imaging of the appropriate organ, in particular, the brain central venous sinus and abdominal splanchnic venous systems for thrombosis plus anti-PF4 ELISA testing in consultation with haematology.     

Main Lesson Box

  • Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) is rare but potentially life-threatening
  • This should be considered when patients present day 4-28 post vaccination with
    •  unusual site thrombosis – splanchnic and/or central venous sinus thrombosis
    • Thrombocytopenia (or falling platelets) and markedly elevated D-dimer
  • Specific testing to detect anti-PF4 antibody is needed to support VITT
  • Treat with non-heparin anticoagulation, IVIG and consider pulsed methylprednisolone. Avoid platelet transfusions


  1. MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots. [press release]. 7th April 2021 2021.
  2. Favaloro EJ, Mohammed S, Donikian D, et al. A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia. Pathology. 2021;53(2):247-56
  3. Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021
  4. Brodard J, Kremer Hovinga JA, Fontana P, et al. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021.
  5. Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12(8):685-98.
  • Jay Hocking1
  • Sanjeev Daya Chunilal2
  • Vivien Chen3
  • Tim Brighton4
  • James Nguyen1
  • Joycelyn Tan1
  • Stephen B N Ting5
  • Huyen Tran6,7

  • 1 Box Hill Hospital
  • 2 Monash Medical Centre
  • 3 Concord Hospital
  • 4 Prince of Wales Hospital and Community Health Services
  • 5 Eastern Health
  • 6 Alfred Hospital
  • 7 Monash University Central Clinical School


Competing interests:

Competing interests: No relevant disclosures


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.